Edition:
United States

Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

997.31USD
--
Change (% chg)

-- (--)
Prev Close
$997.31
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
31
52-wk High
$1,231.90
52-wk Low
$800.00

BMYMP.PK

Chart for BMYMP.PK

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.01
Market Cap(Mil.): $82,274.65
Shares Outstanding(Mil.): 1,671.23
Dividend: 0.39
Yield (%): 3.17

Financials

  BMYMP.PK Industry Sector
P/E (TTM): 24.52 29.51 30.38
EPS (TTM): 2.01 -- --
ROI: 13.97 15.44 14.86
ROE: 21.93 16.62 16.28

Merck, Bristol-Myers agree to settle Keytruda patent suit

Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda.

Jan 20 2017

Merck, Bristol-Myers agree to settle Keytruda patent suit

Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda.

Jan 20 2017

UPDATE 1-Merck, Bristol-Myers agree to settle Keytruda patent suit

Jan 20 Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda.

Jan 20 2017

Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

New YORK Bristol-Myers Squibb Co shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's leading position in the burgeoning immuno-oncolgy field.

Jan 20 2017

UPDATE 1-Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

New YORK, Jan 20 Bristol-Myers Squibb Co shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's leading position in the burgeoning immuno-oncolgy field.

Jan 20 2017

Merck, Bristol-Myers agree to settle Keytruda patent suit

Jan 20 Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve a patent litigation related to its cancer drug, Keytruda.

Jan 20 2017

BRIEF-Bristol-Myers squibb and Ono pharmaceutical enters license agreement with Merck

* Bristol-Myers Squibb and Ono Pharmaceutical Company enter settlement and license agreement with merck to resolve PD-1 antibody patent litigation

Jan 20 2017

Bristol won't seek faster Opdivo/Yervoy lung cancer approval

Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for a combination of its two immunotherapy drugs as an initial treatment for lung cancer.

Jan 19 2017

UPDATE 2-Bristol won't seek faster Opdivo/Yervoy lung cancer approval

Jan 19 Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for a combination of its two immunotherapy drugs as an initial treatment for lung cancer.

Jan 19 2017

Bristol-Myers won't seek accelerated Opdivo lung cancer approval

Jan 19 Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for its combination of two immunotherapy drugs as an initial treatment for lung cancer.

Jan 19 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $114.15 -0.05
Pfizer Inc. (PFE.N) $31.77 +0.07
Merck & Co., Inc. (MRK.N) $62.53 +2.20
Sanofi SA (SASY.PA) €74.60 -1.02
AstraZeneca plc (AZN.L) 4,263.50 -55.00
GlaxoSmithKline plc (GSK.L) 1,526.51 -19.99
Eli Lilly and Co (LLY.N) $76.81 -0.03
Roche Holding Ltd. (ROG.S) CHF231.70 -1.80
Roche Holding Ltd. (RO.S) CHF234.90 -1.20

Earnings vs. Estimates